{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:58:44Z","timestamp":1788026324119,"version":"build-2784847793"},"reference-count":25,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Amlitelimab, a fully human, nondepleting, anti\u2010OX40 ligand monoclonal antibody, demonstrated reductions in lesional and pruritic endpoints in adults with moderate\u2010to\u2010severe atopic dermatitis (AD) in phase 2a and 2b trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Here, we examined the effect and durability of amlitelimab on clinical outcome assessments (COAs) in the randomized STREAM\u2010AD phase 2b trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with moderate\u2010to\u2010severe AD with prior inadequate response to or inadvisability of topical medications received subcutaneous amlitelimab (250\u2009mg with 500\u2010mg loading dose, 250\u2009mg, 125\u2009mg or 62.5\u2009mg) or placebo every 4\u2009weeks in Part 1 (Weeks 0\u201324; 1:1:1:1:1 randomization). In Part 2, Week 24 clinical responders (defined as patients achieving Investigator Global Assessment [IGA] 0\/1 and\/or \u2265\u200975% reduction in the Eczema Area and Severity Index [EASI\u201075]) were rerandomized 3:1 to withdraw or continue amlitelimab pre\u2013Week 24 dose through Week 52. COAs, including SCORing Atopic Dermatitis, affected body surface area, Patient\u2010Oriented Eczema Measure, Dermatology Life Quality Index and Atopic Dermatitis Control Tool, were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 390 randomized patients in Part 1, 190 were rerandomized in Part 2. Significant improvements in COAs were observed with all amlitelimab doses versus placebo at Week 24 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05 for all COAs). At Week 24, the majority of clinical responders achieved meaningful changes in COAs. At Week 52, these improvements were maintained in the majority of patients who achieved COA improvements at Week 24, regardless of treatment continuation or withdrawal during the 28\u2010week Part 2 period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Amlitelimab treatment led to clinically meaningful improvements in COAs by Week 24 versus placebo. COA improvements were maintained at Week 52 in patients continuing amlitelimab, as well as in patients who withdrew from amlitelimab, supporting the durable response of amlitelimab and the viability of extended drug dosing, which may ease treatment burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov\n                      <jats:bold>Identifier:<\/jats:bold>\n                      NCT05131477.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.20877","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T11:40:10Z","timestamp":1753357210000},"page":"2113-2120","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Improvement and maintenance of clinical outcome assessments in atopic dermatitis with amlitelimab"],"prefix":"10.1111","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2633-985X","authenticated-orcid":false,"given":"Andrew","family":"Blauvelt","sequence":"first","affiliation":[{"name":"Blauvelt Consulting LLC  Annapolis Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6510-399X","authenticated-orcid":false,"given":"Raj","family":"Chovatiya","sequence":"additional","affiliation":[{"name":"Chicago Medical School Rosalind Franklin University of Medicine and Science  North Chicago Illinois USA"},{"name":"Center for Medical Dermatology and Immunology Research  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Department of Medicine, Division of Rheumatology University of Texas Southwestern Medical Center, O'Donnell School of Public Health  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3944-252X","authenticated-orcid":false,"given":"Stephan","family":"Weidinger","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy University Hospital Schleswig\u2010Holstein  Kiel Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5574-198X","authenticated-orcid":false,"given":"Ken","family":"Igawa","sequence":"additional","affiliation":[{"name":"Department of Dermatology Dokkyo Medical University  Tochigi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9710-3799","authenticated-orcid":false,"given":"Ella","family":"Brookes","sequence":"additional","affiliation":[{"name":"Sanofi, Reading  UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Weber","sequence":"additional","affiliation":[{"name":"Sanofi  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wang","sequence":"additional","affiliation":[{"name":"Sanofi  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cori","family":"Gray","sequence":"additional","affiliation":[{"name":"Sanofi  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572\u2010018\u20100001\u2010z"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403\u2010024\u201003130\u2010w"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.03.037"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010022\u201000819\u20106"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.03.017"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15641"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2023.11.009"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.10.031"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad240"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan3085"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells13070587"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2539"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398\u20109995.2011.02719.x"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16367"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1159\/000365390"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1699516"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19574"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.3617"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.05.075"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19391"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11255\u2010024\u201004028\u20102"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0278293"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.2147\/ppa.S239196"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271\u2010015\u20100136\u2010x"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1293185"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.20877","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.20877","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.20877","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T11:28:41Z","timestamp":1772969321000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.20877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1111\/jdv.20877"],"URL":"https:\/\/doi.org\/10.1111\/jdv.20877","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"2025-04-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}